ArticleThe Journal of clinical endocrinology and metabolism2013
Variation in the management of thyroid cancer.
Article in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980103 (Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Follow-up and transition of care for low recurrence risk thyroid cancer patients in Canada.European thyroid journal · 2025Guideline
- Health-related quality of life in cancer survivors 5 years after total thyroidectomy: a population-based study.Journal of the Endocrine Society · 2026Article
- Intermediate risk thyroid cancer management: physician survey.Journal of the Endocrine Society · 2026Article
- Patient Perspectives Toward a Decision Aid for Radioactive Iodine Treatment for Intermediate Risk Thyroid Cancer.International journal of behavioral medicine · 2025Article
- Article
- The overtreatment of papillary thyroid microcarcinoma in the community.American journal of surgery · 2024Article
- Evolution in the management of thyroid surgery over a period of 15 years in a Belgian center.BMC surgery · 2024Article
- Racial and Ethnic Disparities in Appropriate Thyroid Cancer Treatment, Before and After the Release of the 2015 American Thyroid Association Guidelines.Annals of surgical oncology · 2023Article
- Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).Thyroid : official journal of the American Thyroid Association · 2022Article
- Physician Specialties Involved in Thyroid Cancer Diagnosis and Treatment: Implications for Improving Health Care Disparities.The Journal of clinical endocrinology and metabolism · 2022Article
- Physician management of thyroid cancer patients' worry.Journal of cancer survivorship : research and practice · 2021Article
- Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2021Article
- Microscopic positive surgical margins in thyroid carcinoma: a proposal for thyroid oncology teams.Langenbeck's archives of surgery · 2021Review
- Understanding surgical decision-making in older adults with differentiated thyroid cancer: A discrete choice experiment.Surgery · 2021Article
- Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer Recurrence.JAMA otolaryngology-- head & neck surgery · 2020Article
- Primary Care Provider Involvement in Thyroid Cancer Survivorship Care.The Journal of clinical endocrinology and metabolism · 2020Article
- Testing for Afirma in Thyroid Nodules with High-Risk Indeterminate Cytology (TIR3B): First Italian Experience.Endocrine pathology · 2020Article
- Role of Patient Maximizing-Minimizing Preferences in Thyroid Cancer Surveillance.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Radioactive iodine in differentiated thyroid cancer: a national database perspective.Endocrine-related cancer · 2019Article
- Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
contextLittle is known about practice patterns in thyroid cancer, a cancer that is increasing in incidence.
objectiveWe sought to identify aspects of thyroid cancer management that have the greatest variation. DESIGN/SETTING/
participantsWe surveyed 944 physicians involved in thyroid cancer care from 251 hospitals affiliated with the US National Cancer Database. Physicians were asked questions in the following four domains: thyroid surgery, radioactive iodine use, thyroid hormone replacement postsurgery, and long-term thyroid cancer management. We calculated the ratio of observed variation to hypothetical maximum variation under the assumed distribution of the response. Ratios closer to 1 indicate greater variation.
resultsWe had a 66% response rate. We found variation in multiple aspects of thyroid cancer management, including the role of central lymph node dissections (variation, 0.99; 95% confidence interval [CI], 0.98-1.00), the role of pretreatment scans before radioactive iodine treatment (variation, 1.00; 95% CI, 0.98-1.00), and all aspects of long-term thyroid cancer management, including applications of ultrasound (variation, 0.97; 95% CI, 0.93-0.99) and radioactive iodine scans (variation, 0.99; 95% CI, 0.97-1.00). For the management of small thyroid cancers, variation exists in all domains, including optimal extent of surgery (variation, 0.91; 95% CI, 0.88-0.94) and the role of both radioactive iodine treatment (variation, 0.91; 95% CI, 0.89-0.93) and suppressive doses of thyroid hormone replacement (variation, 1.00; 95% CI, 0.99-1.00).
conclusionWe identified areas of variation in thyroid cancer management. To reduce the variation and improve the management of thyroid cancer, there is a need for more research and more research dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.